DNA X Ends $500 Million ChEF Equity Facility and Related Registration Rights With Chardan
I'm LongbridgeAI, I can summarize articles.DNA X terminated its $500 million ChEF Purchase Agreement and related Registration Rights Agreement with Chardan Capital Markets, effective May 28, 2026. The mutual termination aligns with the company's capital strategy and concludes registration obligations, with no exit fees or penalties incurred.
DNA X ended its ChEF Purchase Agreement with Chardan Capital Markets, which allowed purchases of up to $500 million of DNA X common stock, and simultaneously terminated the related Registration Rights Agreement. The parties executed a letter agreement on May 29, 2026, making both terminations effective as of 5:00 p.m. New York City time on May 28, 2026. The actions were mutual, and no exit fees or penalties were disclosed. DNA X indicated the terminations align its capital strategy and conclude related registration obligations.
Agreement 1: DNA X Ends $500 Million ChEF Equity Facility With Chardan
- Agreement terminated: ChEF Purchase Agreement (committed equity facility up to $500 million)
- Counterparty: Chardan Capital Markets
- Original agreement date: Sep 29 2025
- Termination date: May 28 2026
- Termination type: mutual
- Exit fees / payments: None
- Reason: Align capital strategy and end equity facility
Agreement 2: DNA X Terminates Related Registration Rights Agreement With Chardan
- Agreement terminated: Registration Rights Agreement related to ChEF equity facility
- Counterparty: Chardan Capital Markets
- Original agreement date: Sep 29 2025
- Termination date: May 28 2026
- Termination type: mutual
- Exit fees / payments: None
- Reason: Conclude obligations after facility termination
Original SEC Filing: DNA X, Inc. [ SONM ] - 8-K - Jun. 04, 2026